Barriers to routine G6PD testing prior to treatment with primaquine

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1475-2875

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: Barriers to routine G6PD testing prior to treatment with primaquine ; volume:16 ; number:1 ; day:10 ; month:8 ; year:2017 ; pages:1-10 ; date:12.2017
Malaria journal ; 16, Heft 1 (10.8.2017), 1-10, 12.2017

Classification: Soziale Probleme, Sozialdienste, Versicherungen

Keyword: Infektion
Infektiologie

Creator: Ley, Benedikt

Contributor: Thriemer, Kamala
Jaswal, Jessica
Poirot, Eugenie
Alam, Mohammad Shafiul
Phru, Ching Swe
Khan, Wasif Ali
Dysoley, Lek
Qi, Gao
Kheong, Chong Chee
Shamsudin, Ummi Kalthom
Chen, Ingrid
Hwang, Jimee
Gosling, Roly
Price, Ric N.
SpringerLink (Online service)

DOI: 10.1186/s12936-017-1981-y

URN: urn:nbn:de:1111-2017102618975

Rights: Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:33 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Ley, Benedikt
Thriemer, Kamala
Jaswal, Jessica
Poirot, Eugenie
Alam, Mohammad Shafiul
Phru, Ching Swe
Khan, Wasif Ali
Dysoley, Lek
Qi, Gao
Kheong, Chong Chee
Shamsudin, Ummi Kalthom
Chen, Ingrid
Hwang, Jimee
Gosling, Roly
Price, Ric N.
SpringerLink (Online service)

Other Objects (12)

Primaquine-induced haemolysis in females heterozygous for G6PD deficiency

Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination

Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia

Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation

Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common

Correction to: NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms

G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine-induced haemolysis in females heterozygous for G6PD deficiency

Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination

Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia

Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation

Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common

Correction to: NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms

G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine-induced haemolysis in females heterozygous for G6PD deficiency

Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination

Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia

Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation

Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common

Correction to: NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms

G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

Barriers to routine G6PD testing prior to treatment with primaquine

Object Details

References and Relationships

Classification and Topics

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Primaquine-induced haemolysis in females heterozygous for G6PD deficiency

Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination

Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia

Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation

Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common

Correction to: NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms

G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine-induced haemolysis in females heterozygous for G6PD deficiency

Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination

Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia

Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation

Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common

Correction to: NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms

G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine-induced haemolysis in females heterozygous for G6PD deficiency

Safety of primaquine given to people with G6PD deficiency: systematic review of prospective studies

G6PD deficiency, primaquine treatment, and risk of haemolysis in malaria-infected patients

Review of the interactions between G6PD deficiency and primaquine therapy for malaria control and elimination

Prevalence and distribution of G6PD deficiency: implication for the use of primaquine in malaria treatment in Ethiopia

Spectrophotometry assays to determine G6PD activity from Trinity Biotech and Pointe Scientific G6PD show good correlation

Rationale for recommending a lower dose of primaquine as a Plasmodium falciparum gametocytocide in populations where G6PD deficiency is common

Correction to: NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms

G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

Correction: G6PD deficiency among malaria-infected national groups at the western part of Myanmar with implications for primaquine use in malaria elimination

NF-κB and pSTAT3 synergistically drive G6PD overexpression and facilitate sensitivity to G6PD inhibition in ccRCC

Related objects

Reset password